Grants and Contracts Details
The goal of this trial is to examine the therapeutic effects of intranasally-administered insulin (INI) on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD).
|Effective start/end date||3/1/13 → 4/30/16|
- University of California San Diego Health: $19,500.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.